Drug Trial Radar · NCT04202653
Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jan 1, 2020
Primary completion
Jun 30, 2023
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- Tongji HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- First posted
- Dec 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-center, randomized, prospective, open-label Phase 2 Clinical trial to evaluate efficacy and safety of ETV and TQ-A3334 combinated with/without inhibitor of TQ-B2450 versus ETV alone in chronic hepatitis B patients. Patients were randomized to one of 3 different antiviral treatment.
Conditions
- Chronic Hepatitis b
Interventions
ETVDrug
entecavir 0.5 mg qd
TQ-A3334Drug
TQ-A3334 po qw
TQ-B2450Drug
TQ-B2450 q3w iv
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in HBsAg quantification at week 24Time frame: week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tongji Hospital
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.